The Collapse of the Antibiotics Sector
Ryan Cirz is the CEO/CSO of Revagenix, Inc., a preclinical-stage biopharmaceutical company dedicated to the discovery and development of life-changing and life-saving medicines. Previously, he was founder and vice president of research at Achaogen where he oversaw the early-stage (pre-investigational new drug) pipeline and provided intellectual insight/support to all things related to infectious diseases, including late-stage development, commercialization, and medical affairs. Achaogen focused on discovering, developing, and commercializing innovative antibacterials to treat multi-drug resistant infections.
Cirz earned his Ph.D. in biochemistry from the Scripps Research Institute and his Bachelor of Science in biochemistry and molecular biology from Penn State University.